...

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: About the safety and how well people tolerate sacituzumab tirumotecan alone or with chemotherapy How many people have the cancer respond (get smaller or go away) to treatment


Why this Research Matters

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: About the safety and how well people tolerate sacituzumab tirumotecan alone or with chemotherapy How many people have the cancer respond (get smaller or go away) to treatment


Who can Participate

Adult

Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study. https://clinicaltrials.gov/study/NCT06428409?term=NCT06428409&rank=1


Study ID

Protocol Number: 24-1250
More information available at ClinicalTrials.gov: NCT06428409

Meet the Team

Image of Principal Investigator

Sarah Davis, MD

Principal Investigator


Categories

Locations